.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Uncover prior art in abandoned patent applications and expired patents
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 8,841,310

« Back to Dashboard

Which drugs does patent 8,841,310 protect, and when does it expire?

Patent 8,841,310 protects COMPLERA and is included in one NDA. There has been one Paragraph IV challenge on Complera.

This patent has one hundred and sixty-six patent family members in thirty-eight countries.

Summary for Patent: 8,841,310

Title:Combinations of a pyrimidine containing NNRTI with RT inhibitors
Abstract: The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and/or nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.
Inventor(s): Stoffels; Paul (Hoogstraten, BE)
Assignee: Janssen R & D Ireland (Eastgate Village, Eastgate Little Island, Co. Cork, IE)
Application Number:12/574,881
Patent Claim Types:
see list of patent claims
Compound; Formulation; Composition; Dosage form; Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Gilead Sciences Inc
COMPLERA
emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
TABLET;ORAL202123-001Aug 10, 2011RXYesYes8,841,310► SubscribeY TREATMENT OF HIV INFECTION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,841,310

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03103275Sep 3, 2003
03103319Sep 8, 2003
03103335Sep 10, 2003
03103668Oct 2, 2003

Non-Orange Book Patents for Patent: 8,841,310

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,125,879HIV inhibiting pyrimidines derivatives► Subscribe
7,638,522Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl- ]amino] benzonitrile► Subscribe
8,101,629Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl- ]amino]benzonitrile► Subscribe
8,080,551HIV inhibiting pyrimidines derivatives► Subscribe
7,956,063Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl- ]amino]benzonitrile► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,841,310

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Netherlands300781► Subscribe
Mexico2007002595► Subscribe
Mexico2007002594► Subscribe
MexicoPA06002437► Subscribe
MexicoPA04001401► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc